Skeletal-Related Events in Patients With Multiple Myeloma: A Comprehensive Retrospective Cohort Study
10.3346/jkms.2024.39.e175
- Author:
Ji Yun LEE
1
;
Ju-Hyun LEE
;
Jeongmin SEO
;
Minsu KANG
;
Eun Hee JUNG
;
Sang-A KIM
;
Koung Jin SUH
;
Ji-Won KIM
;
Se Hyun KIM
;
Jeong-Ok LEE
;
Jin Won KIM
;
Yu Jung KIM
;
Keun-Wook LEE
;
Jee Hyun KIM
;
Jong Seok LEE
;
Soo-Mee BANG
Author Information
1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea
- Publication Type:Original Article
- From:Journal of Korean Medical Science
2024;39(22):e175-
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Multiple myeloma (MM) patients are at risk of skeletal-related events (SREs) like spinal cord compression, pathologic fractures, bone surgery, and radiation to bone. Realworld data regarding SREs in MM are limited.
Methods:We conducted a large, retrospective, nationwide cohort study using the Korean Health Insurance Review and Assessment Service (HIRA) database from 2007 to 2018.
Results:Over a 12-year study period, we identified 6,717 patients who developed symptomatic MM. After a median follow-up of 35.1 months (interquartile range [IQR], 20.8–58.2 months), 43.6% of these patients experienced SREs, and 39.6% had four or more SREs. One in five patients (20.0%) experienced pathologic fractures within the first year of follow-up. The median time to first SRE was 9.6 months (IQR, 1.2–25.8 months), with 3.0 months in the group with prior SREs and 19.8 months in the group without prior SREs.During follow-up, 78.5% of patients received bisphosphonates. Multiple logistic regression analysis revealed several factors associated with an increased risk of SREs, including being female (odds ratio [OR], 1.44), aged 50 or older (OR, 1.87), having cerebrovascular disease (OR, 1.34), undergoing first-line chemotherapy regimens not containing bortezomib or lenalidomide (OR, 1.49), and being in the group with prior SREs and bisphosphonate use (OR, 5.63), compared to the group without prior SREs and without bisphosphonate use.
Conclusion:This population-based study is the first to report the incidence and risk factors of SREs in Korean MM patients, which can be used to assess their bone health.
